CancerDrs Find care

Stomach Cancer clinical trials in Arkansas

12 actively recruiting stomach cancer trials at 7 sites across Arkansas.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CARTI Cancer Center — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting NIH

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Sites in Arkansas:
  • Baptist Health Medical Center - Little Rock — Little Rock, Arkansas
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Arkansas:
  • Research Site — Springdale, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Arkansas:
  • Highlands Oncology Group — Fayetteville, Arkansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Arkansas:
  • Highlands Oncology Group — Fayetteville, Arkansas
  • Highlands Oncology Group — Rogers, Arkansas
  • Highlands Oncology Group — Springdale, Arkansas
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults wi…

Sponsor: NiKang Therapeutics, Inc.
NCT ID: NCT06586957
Sites in Arkansas:
  • University of Arkansas Medical School — Little Rock, Arkansas
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CARTI Cancer Center — Little Rock, Arkansas
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
  • CARTI Cancer Center — Little Rock, Arkansas
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
  • CARTI Cancer Center — Little Rock, Arkansas
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic te…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07091617
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CARTI Cancer Center — Little Rock, Arkansas
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arkansas:
  • Massive Bio SYNERGY-AI site — Little Rock, Arkansas
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20